News
KIN
--
0.00%
--
Earnings Preview: Kindred Biosciences (KIN) Q2 Earnings Expected to Decline
Kindred Bio (KIN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Zacks · 4d ago
INVESTIGATION ALERT: Monteverde & Associates PC Pursues Investigating the Following Merger
NEW YORK, NY / ACCESSWIRE / July 26, 2021 / Juan Monteverde, founder and managing partner at Monteverde & Associates PC, a national securities firm rated Top 50 in the 2018-2020 ISS Securities Class Action Services Report and headquartered at the Empire St...
ACCESSWIRE · 6d ago
The Kindred Biosciences (NASDAQ:KIN) Share Price Is Up 142% And Shareholders Are Boasting About It
The most you can lose on any stock (assuming you don't use leverage) is 100% of your money. But on a lighter note, a...
Simply Wall St. · 07/13 08:34
Insider Trends: Kindred Biosciences Insider Continues 90-Day Selling Trend
MT Newswires · 07/07 12:12
SHAREHOLDER INVESTIGATION: Halper Sadeh LLP Investigates the Following Companies - KIN, SYKE, USCR, ONEM, QTS, MCF
/PRNewswire/ -- Halper Sadeh LLP, a global investor rights law firm, announces it is investigating the following companies:
PR Newswire - PRF · 06/21 13:00
Looking Into Kindred Biosciences's Return On Capital Employed
Kindred Biosciences (NASDAQ:KIN) reported Q1 sales of $2.40 million. Earnings fell to a loss of $9.17 million, resulting in a 11.54% decrease from last quarter. In Q4, Kindred Biosciences brought in $951.00 thousand in sales but lost $10.36 million in earn...
Benzinga · 06/18 14:19
Elanco Animal Health to Snap up Kindred Biosciences; Shares Soar
Elanco Animal Health (ELAN) inked a deal to acquire Kindred Biosciences (KIN), a biopharmaceutical company that develops novel pet therapeutics based on validated human targets, at $9.25 per share for a total consideration of $440 million. Shares of both c...
SmarterAnalyst · 06/17 09:56
Lake Street Downgrades Kindred Biosciences to Hold from Buy, Adjusts Price Target to $9.25 from $12
MT Newswires · 06/17 09:41
48 Biggest Movers From Yesterday
Gainers Gaucho Group Holdings, Inc. (NASDAQ: VINO) shares jumped 95.1% to close at $7.98 on Wednesday. Gaucho Group highlighted the launch of its Amazon Storefront.
Benzinga · 06/17 09:07
--HC Wainwright Downgrades Kindred Biosciences to Neutral From Buy, Adjusts Price Target to $9.25 From $9
MT Newswires · 06/17 07:01
SHAREHOLDER NOTICE: Brodsky & Smith Announces an Investigation of Kindred Biosciences, Inc. (NASDAQ:KIN)
BALA CYNWYD, PA / ACCESSWIRE / June 16, 2021 / Law office of Brodsky & Smith announces that it is investigating potential claims against the Board of Directors of Kindred Biosciences, Inc. (“KindredBio” or the “Company”) (NASDAQ:KIN) for possible breaches ...
ACCESSWIRE · 06/16 23:03
Elanco deal for Kindred could better position company against Zoetis - Barron's
Marko Geber/DigitalVision via Getty Images Elanco Animal Health's (ELAN) $440M deal for Kindred BioSciences (KIN) could better position the company to compete against Zoetis (ZTS) in the pet dermatology space,
Seekingalpha · 06/16 21:26
Stocks making the biggest moves midday: GM, H&R Block, Citigroup and more
These are the stocks posting the largest moves in midday trading.
CNBC.com · 06/16 16:35
Why Kindred Biosciences, Aprea, Catabasis And Inhibikase Are Moving Today
Kindred Biosciences, Inc. (NASDAQ: KIN), Aprea Therapeutics, Inc. (NASDAQ: APRE), Catabasis Pharmaceuticals, Inc.
Benzinga · 06/16 16:30
Kindred Biosciences Shares Higher After News of Elanco Deal
marketwatch.com · 06/16 15:55
Elanco Is Looking To Challenge Zoetis, Will The $440 Million Kindred Buyout Help?
Elanco Animal Health said Wednesday it would buy Kindred Biosciences for roughly $440 million, sending KIN stock soaring.
Investor's Business Daily · 06/16 15:09
Opthea, Kindred Biosciences leads healthcare gainers; Inhibikase Therapeutics, Paratek Pharmaceuticals among major losers
Gainers: Opthea (OPT) +47%, Kindred Biosciences (KIN) +45%, Aprea Therapeutics (APRE) +38%, Altimmune (ALT) +21%, BriaCell Therapeutics (BCTX) +15%.Losers: Inhibikase Therapeutics (IKT) -24%, Paratek Pharmaceuticals (PRTK) -14%, Fusion Pharmaceuticals (FUS...
Seekingalpha · 06/16 15:02
Thinking about buying stock in Kindred Biosciences, Applied UV, Sundial Growers, Vista Gold, or Arcadia Biosciences?
/PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for KIN, AUVI, SNDL, VGZ, and RKDA.
PR Newswire - PRF · 06/16 14:50
Elanco Strikes Deal to Better Compete With Rival Zoetis in Pet Dermatology
marketwatch.com · 06/16 14:44
Webull provides a variety of real-time KIN stock news. You can receive the latest news about Kindred Bio through multiple platforms. This information may help you make smarter investment decisions.
About KIN
Kindred Biosciences, Inc. is a development-stage biopharmaceutical company. The Company is focused on developing therapies for pets. The Company's product pipeline consists of small molecules and biologics for a range of indications in dogs, cats and horses. The Company is developing product candidates for over 20 indications and focused on small molecule products and canine and feline biologics products. The Company is developing antibodies that targets canine Interleukin 17A (IL-17a), Interleukin 4A (IL-4Ra), Interleukin 3 (IL-3), CD-20, Immunoglobulin E (IgE), tumor necrosis factors (TNF) and other validated targets. The Company's lead product candidates are Zimeta, which is indicated for the treatment of fever in horses, and KIND-010 for management of weight loss in cats. The Company's other product candidates include KIND-010, KIND-014, KIND-015, KIND-510, KIND-502, KIND-0888, KIND-509, and several antibodies that target cytokines involved in atopic dermatitis.